Mucosal T Cells Expressing High Levels of IL-7 Receptor Are Potential Targets for Treatment of Chronic Colitis

Motomi Yamazaki, Tomoharu Yajima, Masanobu Tanabe, Kazuto Fukui, Eriko Okada, Ryuichi Okamoto, Shigeru Oshima, Tetsuya Nakamura, Takanori Kanai, Masahiro Uehira, Tsutomu Takeuchi, Hiromichi Ishikawa, Toshifumi Hibi and Mamoru Watanabe

*J Immunol* 2003; 171:1556-1563; doi: 10.4049/jimmunol.171.3.1556
http://www.j immunol.org/content/171/3/1556

Why *The JI*?

- **Rapid Reviews!** 30 days* from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

References This article **cites 28 articles**, 10 of which you can access for free at:
http://www.jimmunol.org/content/171/3/1556.full#ref-list-1

Subscription Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Mucosal T Cells Expressing High Levels of IL-7 Receptor Are Potential Targets for Treatment of Chronic Colitis

Motomi Yamazaki,* Tomoharu Yajima,† Masanobu Tanabe,‡ Kazuto Fukui,† Eriko Okada,* Ryuichi Okamoto,* Shigeru Oshima,* Tetsuya Nakamura,* Takanori Kanai,* Masahiro Uehira,¶ Tsutomu Takeuchi,‡ Hiromichi Ishikawa,§ Toshifumi Hibi,† and Mamoru Watanabe2*


Interleukin-7 is a nonredundant cytokine for the development of lymphocyte lineage cells (1). Abundant IL-7 expression has been demonstrated in the bone marrow stroma, thymus, spleen, and liver. However, a potential role for IL-7 in peripheral nonlymphoid tissues remained unclear. We have demonstrated that IL-7 is produced by intestinal epithelial cells and regulates mucosal lymphocytes (2). Following our study, other investigators demonstrated that IL-7 is crucial for the development of TCR-γδ T cells and the formation of Peyer’s patches in the intestinal mucosa of the mouse (3–6). TCR-γδ intraepithelial lymphocytes (IELs) are completely absent from IL-7 knock out mice, and their number is extremely decreased in IL-7 knockout mice. It has been demonstrated that IL-7 expression under intestinal fatty acid binding protein promoter in intestinal epithelial cells of IL-7 knockout mice was sufficient for the development of extrathymic TCR-γδ IELs (7). The effect of IL-7 expression on the development of Peyer’s patches further emphasized the critical role for IL-7 in the ontogeny of the mucosal immune system. Moreover, we have recently demonstrated the presence of a novel lymphoid tissue, designated cryptopatches, in murine intestinal mucosa, where clusters of IL-7R+ c-Kit+ lympho-hemopoietic progenitor develop in an IL-7-dependent fashion (8, 9). All these findings indicated that intestinal epithelial cell-derived IL-7 plays a crucial role in the organization of mucosal lymphoid tissues and in the regulation of the normal immune response in the intestinal mucosa.

The IL-7/IL-7R-dependent signaling pathway plays a crucial role in regulating the immune response in intestinal mucosa. Here we demonstrate the pivotal role of this pathway in the development and treatment of chronic colitis. T cells expressing high levels of IL-7R were substantially infiltrated in the chronic inflamed mucosa of TCR α-chain knockout mice and IL-7 transgenic mice. Transfer of mucosal T cells expressing high levels of IL-7R, but not T cells expressing low levels of IL-7R, from these mice into recombinase-activating gene-2−/− mice induced chronic colitis. Selective elimination of T cells expressing high levels of IL-7R by administrating small amounts of toxin-conjugated anti-IL-7R Ab completely ameliorated established, ongoing colitis. These findings provide evidence that therapeutic approaches targeting mucosal T cells expressing high levels of IL-7R are effective in the treatment of chronic intestinal inflammation and may be feasible for use in the therapy of human inflammatory bowel disease.
of cells with low or intermediate expression of IL-7R. We have shown that the mucosal IL-7R-dependent signaling pathway in the colonic mucosa was dysregulated in human ulcerative colitis. Therefore, our results indicated the potential of targeting mucosal T cells expressing high levels of IL-7R for the therapy of human inflammatory bowel disease.

Materials and Methods

Mice

TCR γ-chain knockout (TCRγ−/−) mice with a background of C57BL/6 were purchased from The Jackson Laboratory (Bar Harbor, ME). C57BL/6 recombine-activating gene-2 (RAG-2)−/− mice were provided by Central Laboratories for Experimental Animals (Kawasaki, Japan), BALB/c and C.B.17-SCID mice were purchased from Japan Clea (Tokyo, Japan). IL-7 Tg mice carrying murine IL-7 cDNA under the control of the SRα promoter were established as previously described (10). In some experiments wild-type littermates were used as controls. Mice were maintained at the animal care facility of Tokyo Medical and Dental University. The review board of the university approved our experimental animal studies.

Induction of experimentally induced colitis

For chemically induced colitis, we used dextran sulfate sodium (DSS)-induced, oxazolone-induced, and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-immune colitis models (12). These models developed acute or short term colitis. CD4+CD45RBhigh T cell transfer model using C.B.17-SCID mice (13) was also used as a chronic colitis model.

Histological and immunohistochemical analyses

Colonic tissues were embedded at −80°C. Six-micrometer sections were placed on glass slides and stained with H&E. The severity of colitis was graded by histological findings. The disease score (0, normal; 1, mild; 2, moderate; 3, severe colitis) in stained sections were determined according to the degree of inflammation as previously described (14). For the staining of IL-7R+ cells, sections were incubated with 10 μg/ml of anti-IL-7R mAb (2G12; BD PharMingen) and then stained with PE-streptavidin (BD PharMingen). Standard two-color flow cytometric analysis was performed using FACSCalibur (BD Biosciences). The purity of IL-7R+ T cells was confirmed by flow cytometry and was >97%. The purified IL-7R+ T cells were i.p. transferred into RAG-2−/− mice (8–10 wk of age). Mice were sacrificed 4–6 wk after cell transfer for analysis. In some experiments purified CD4+ IL-7R+ T cells from colitic mice were further separated into cells expressing high and low levels of IL-7R. In the histogram of IL-7R expression determined by flow cytometry, the top 30% of the cells were separated as IL-7Rhigh cells and the bottom 30% of the cells were separated as IL-7Rlow. We then transferred 5 × 10^6 of either IL-7Rhigh or IL-7R−/− mucosal T cells into RAG-2−/− mice.

Administration of saporin-conjugated anti-IL-7R mAb

We conjugated the plant toxin saporin to our anti-IL-7R mAb (A7R34) as a custom service at Advance Targeting System (Carlsbad, CA). We then treated chronic colitis in TCRα−/− mice from 20–24 wk of age by i.p. injection of this toxin-conjugated anti-IL-7R mAb at a dose of 10 μg, once a week for 6 wk. As a control, the same amount of a mixture of free anti-IL-7R mAb (10 μg) and saporin (unconjugated) was injected. All mice were sacrificed on the day after the last treatment, and colitis lesions were evaluated.

Statistical analysis

The results were expressed as the mean ± SD. For statistical analysis, we used the program StatView for Macintosh (Abacus Concepts, Berkeley, CA) and MS Office (Excel; Microsoft, Redmond, WA) and analyzed the data with Student’s t test.

Results

Infiltration of T cells expressing high levels of IL-7R in the colonic mucosa of TCRγ−/− mice with chronic colitis

We assessed whether the mucosal IL-7R-dependent immune response is dysregulated in the development of acute and chronic intestinal inflammation. As acute or short term colitis models, we used chemically induced colitis models, including DSS-induced, oxazolone-induced, and TNBS-immune colitis models. As chronic or long term colitis models, CD4+CD45RBhigh T cell transfer into the SCID mice model and TCRγ−/− mice (14) were examined. No changes in IL-7/IL-7R-mediated immune responses were observed in the inflamed colonic mucosa of chemically induced acute colitis models (data not shown). TNBS-treated mice developed short term colitis, but IL-7R+ T cells did not infiltrate the lamina propria of the inflamed mucosa. This was also observed in oxazolone-treated mice and the DSS-induced mouse colitis model. In contrast, IL-7R+ T cells were remarkably infiltrated in lamina propria of chronically inflamed mucosa of CD4+CD45RBhigh T cell-transferred SCID mice. These results are consistent with the findings in IL-7 Tg mice and in human ulcerative colitis. The results suggested that mucosal IL-7R-dependent immune responses were involved in chronic intestinal inflammation, but not in acute inflammation.

To prove this possibility, we then focused on TCRα−/− mice. Our TCRα−/− mice spontaneously developed chronic colitis at 8–16 wk of age (14). We assessed the expression of IL-7R on infiltrated mucosal T cells before and after the development of colitis. In TCRα−/− mice, previous reports showed that CD4+TCRαdim T cells mediate chronic colitis (15, 16). Flow cytometric analysis of isolated LPLs demonstrated that CD4+ TCRαdim T cells were demonstrable in the colonic mucosa of both colitis-free TCRα−/− mice and mice with chronic colitis. However, IL-7R+ TCRαdim T cells were remarkably increased in colonic LPLs after the development of colitis (Fig. 1A). In the colonic mucosa of colitis-free TCRα−/− mice, TCRαdim LPLs were demonstrable, but only half of these cells expressed IL-7R. In contrast, almost all TCRαdim cells in the colonic mucosa of TCRα−/−
mice with chronic colitis expressed IL-7R. Moreover, the degree of IL-7R expression in CD4⁺ TCRβdim LPLs of the colonic mucosa of TCRα⁻/- mice with chronic colitis was significantly ($p < 0.001$) higher compared with that in the colonic mucosa of colitis-free TCRα⁻/- mice (Fig. 1B). The degrees of IL-7R expression determined by the mean fluorescence intensity in flow cytometric histogram were 553 ± 21 and 41 ± 5, respectively. To confirm that infiltrated CD4⁺ T cells expressed IL-7R at high level in the chronic inflamed colonic mucosa, we performed immunohistochemistry. There were only a few IL-7R⁺ cells in the colonic mucosa of colitis-free TCRα⁻/- mice or wild-type mice. In contrast, T cells expressing intense staining signals of IL-7R were predominantly infiltrated in the lamina propria at chronic colitis lesions in TCRα⁻/- mice (Fig. 1C). Most of these infiltrated cells expressed CD4. In addition, IL-7R transcript was up-regulated in chronic colitis lesions, as determined by RT-PCR (data not shown). These results further reinforce the concept that IL-7R-mediated immune responses are dysregulated in chronic intestinal inflammation. The expansion of LPLs expressing high levels of IL-7R in the colonic mucosa was a characteristic feature of the chronic colitis lesion.

Transfer of IL-7Rhigh mucosal T cells induced chronic colitis in immunodeficient mice

To prove the hypothesis that T cells expressing high levels of IL-7R in the lamina propria of the colonic mucosa mediated the development of chronic intestinal inflammation, we first performed transfer experiments of mucosal T cells expressing IL-7R into immunodeficient mice. IL-7R⁺ CD4⁺ T cells were isolated from the colonic mucosa of TCRα⁻/- mice that developed chronic colitis or wild-type mice by sorting and then were transferred into syngeneic RAG-2⁻/- mice (Fig. 2A). Phenotypic analysis of IL-7R⁺ CD4⁺ LPLs from TCRα⁻/- mice with chronic colitis revealed that these isolated cells consisted of 80% TCRβdim and 20% γδ, 95% CD45RBlow and 5% CD45RBhigh, and CD25⁺ cells (Fig. 2B). Cytokine production of isolated IL-7R⁺ CD4⁺ LPLs in TCRα⁻/- mice with chronic colitis and that in wild-type mice after stimulation with anti-CD3 mAb and anti-CD28 mAb were quite different. Isolated IL-7R⁺ CD4⁺ LPLs from TCRα⁻/- mice with chronic colitis produced significantly higher amounts of IL-2 ($p < 0.001$), IFN-γ ($p < 0.05$), and IL-4 ($p < 0.01$) compared with those from wild-type mice (Fig. 2C). IL-10 production was decreased in isolated IL-7R⁺ CD4⁺ LPLs from TCRα⁻/- mice with chronic colitis ($p < 0.05$ compared with that from wild-type mice).

All recipient mice transferred 5 x 10⁵ IL-7R⁺ CD4⁺ LPLs from TCRα⁻/- mice with chronic colitis developed severe colitis within 4–6 wk (Fig. 2D). Colonic inflammation occurred more rapidly and was more severe in the recipient mice compared with the original TCRα⁻/- mice. Histopathological examination of the colonic tissues revealed that inflammatory cell infiltration and goblet cell depletion were prominent throughout the colon. Crypt abscesses, Paneth cell metaplasia, and infiltration of eosinophils were also observed in the inflammatory lesions. These features resembled the histopathological characteristics of the colitic lesion of TCRα⁻/- mice and our IL-7 Tg mice (10, 14–16). In contrast, transfer of IL-7R⁺ CD4⁺ LPLs from wild-type mice into RAG-2⁻/- mice did not produce colitis in the mice during the observation period. In addition, IL-7R⁺ CD4⁺ LPLs from both mice never induced colitis. In the chronic colitis lesion of RAG-2⁻/- mice transferred IL-7R⁺ CD4⁺ LPLs from TCRα⁻/- mice with chronic colitis, IL-7R⁺ T cells were remarkably infiltrated in the lamina propria (Fig. 2D). Flow cytometric analysis revealed that these infiltrated LPLs mainly consisted of TCRβdim, CD4⁺, CD4⁺/CD45RBlow, and CD25⁺ cells (Fig. 2E).

To eliminate the possibility that mucosal T cells expressing high levels of IL-7R, but merely CD4⁺ TCRβdim T cells mediated
To further eliminate the possibility that not IL-7R\textsuperscript{high} mucosal T cell, but TCR\beta\textsuperscript{dim} cells mediated chronic inflammation, we performed another transfer experiment using IL-7R\textsuperscript{−/−} T cells from IL-7 Tg mice. In IL-7 Tg mice, purified IL-7R\textsuperscript{−/−} T cells from colitic lesions of IL-7 Tg mice contained no TCR\beta\textsuperscript{dim} T cells (Fig. 4A). We also sorted IL-7R\textsuperscript{high} and IL-7R\textsuperscript{low} CD4 T cells from the colonic mucosa of IL-7 Tg mice that developed chronic colitis and transferred these sorted cells as well as whole IL-7R\textsuperscript{−/−} T cells into RAG-2\textsuperscript{−/−} mice (Fig. 4B). All recipient mice that were transferred IL-7R\textsuperscript{high} mucosal T cells or whole IL-7R\textsuperscript{−/−} T cells from IL-7 Tg mice developed severe colitis within 4 wk (Fig. 4C). In contrast, transfer of IL-7R\textsuperscript{low} T cells did not induce inflammation. Similar to the transfer experiments with IL-7R\textsuperscript{high} mucosal T cells from TCR\alpha\textsuperscript{-/−} mice, colonic inflammation occurred more rapidly and was more severe in the recipient mice compared with the colitis in original IL-7 Tg mice. Histopathological examination of the colonic tissues of those transferred mice revealed that inflammatory cell infiltration and goblet cell depletion were most prominent throughout the colon. Crypt abscesses, Paneth cell metaplasia, and infiltration of eosinophils were also observed in the colitis lesions. Assessment of the severity of colitis by histological scores showed a significant (p < 0.001) difference between mice transferred IL-7R\textsuperscript{high} LPLs and those given IL-7R\textsuperscript{low} LPLs (Fig. 3C). These results supported the concept that IL-7R\textsuperscript{high} T cells, not merely CD4 TCR\beta\textsuperscript{dim} T cells, in lamina propria of colonic mucosa induced chronic colitis.

chronic inflammation, we performed another set of transfer experiments using purified and sorted IL-7R\textsuperscript{−/−} T cells from the mucosa of TCR\alpha\textsuperscript{-/−} mice with chronic colitis. Purified IL-7R\textsuperscript{−/−} CD4\textsuperscript{+} T cells from chronic colitis were further separated into cells expressing IL-7R at high and low levels. In the flow cytometric histogram of IL-7R expression, the highest 30% of IL-7R-expressing T cells were separated as IL-7R\textsuperscript{high}, and the lowest 30% of IL-7R expressing T cells were separated as IL-7R\textsuperscript{low} (Fig. 3A). We transferred 5 × 10\textsuperscript{5} cells/body of those sorted cells into RAG-2\textsuperscript{−/−} mice. All recipient RAG-2\textsuperscript{−/−} mice that were transferred IL-7R\textsuperscript{high} LPLs developed severe colitis within 4–6 wk after transfer (Fig. 3B). In sharp contrast, none of mice that were transferred IL-7R\textsuperscript{low} LPLs developed colitis during the observation period. Assessment of the severity of colitis examined by histological scores showed a significant (p < 0.001) difference between mice transferred IL-7R\textsuperscript{high} LPLs and those given IL-7R\textsuperscript{low} LPLs (Fig. 3C). These results supported the concept that IL-7R\textsuperscript{high} T cells, not merely CD4 TCR\beta\textsuperscript{dim} T cells, in lamina propria of colonic mucosa induced chronic colitis.

To further eliminate the possibility that not IL-7R\textsuperscript{high} mucosal T cell, but TCR\beta\textsuperscript{dim} cells mediated chronic inflammation, we performed another transfer experiment using IL-7R\textsuperscript{−/−} T cells from IL-7 Tg mice. In IL-7 Tg mice, purified IL-7R\textsuperscript{−/−} T cells from colitic lesions of IL-7 Tg mice contained no TCR\beta\textsuperscript{dim} T cells (Fig. 4A). We also sorted IL-7R\textsuperscript{high} and IL-7R\textsuperscript{low} CD4 T cells from the colonic mucosa of IL-7 Tg mice that developed chronic colitis and transferred these sorted cells as well as whole IL-7R\textsuperscript{−/−} T cells into RAG-2\textsuperscript{−/−} mice (Fig. 4B). All recipient mice that were transferred IL-7R\textsuperscript{high} mucosal T cells or whole IL-7R\textsuperscript{−/−} T cells from IL-7 Tg mice developed severe colitis within 4 wk (Fig. 4C). In contrast, transfer of IL-7R\textsuperscript{low} T cells did not induce inflammation. Similar to the transfer experiments with IL-7R\textsuperscript{high} mucosal T cells from TCR\alpha\textsuperscript{-/−} mice, colonic inflammation occurred more rapidly and was more severe in the recipient mice compared with the colitis in original IL-7 Tg mice. Histopathological examination of the colonic tissues of those transferred mice revealed that inflammatory cell infiltration and goblet cell depletion were most prominent throughout the colon. Crypt abscesses, Paneth cell metaplasia, and infiltration of eosinophils were also observed in the colitis lesions. Assessment of the severity of colitis by histological scores showed a significant (p < 0.001) difference between mice transferred IL-7R\textsuperscript{high} LPLs and those given IL-7R\textsuperscript{low} LPLs from the colitic lesion of IL-7 Tg mice (Fig. 4D). All these results indicated that mucosal T cells expressing high levels of IL-7R mediated the development of chronic inflammation.
chronic intestinal inflammation. Therefore, therapeutic approaches targeting IL-7R-mediated immune responses are thought to be feasible.

**Successful treatment of established, ongoing chronic colitis in TCRα−/− mice by selective elimination of LPLs expressing high levels of IL-7R using saporin-conjugated anti-IL-7R Ab**

To correct the dysregulation of mucosal IL-7/IL-7R-mediated immune responses, we attempted to control mucosal T cells expressing high levels of IL-7R by toxin-based destruction of IL-7R-expressing cells. A plant toxin, saporin, was conjugated to our anti-IL-7R mAb (17). In preliminary experiments we confirmed that a low concentration (10 μg/ml) of saporin-conjugated anti-IL-7R mAb inhibited the proliferation of IL-7-dependent cell line DW34 cells expressing IL-7R at a high level, but not of LPLs and spleen cells from wild-type mice. Using 10 μg/ml of this toxin-conjugated anti-IL-7R mAb, we found that this agent did not inhibit the in vitro proliferation of CD4+ spleen cells that expressed IL-7R at low and intermediate levels from wild-type mice, but did inhibit that of IL-7Rhigh T cells from chronically inflamed mucosa of TCRα−/− mice (data not shown). In preliminary experiments treatment of wild-type mice by i.p. injection of small amounts (10 μg/body) of saporin-conjugated anti-IL-7R mAb once a week for 6 wk did not cause any change in the total cell number and phenotypic change in spleen cells or LPLs (data not shown). Depletion of IL-7R+ or CD4+ cells was not observed even after six treatments with 10 μg/body of saporin-conjugated anti-IL-7R mAb. We then assessed the therapeutic effect of this saporin-conjugated anti-IL-7R mAb in the established, ongoing colitis of TCRα−/− mice. Since all untreated TCRα−/− mice developed colitis within 16 wk of age in our series, we started the treatment of established colitis in these mice at 20 wk of age. We treated chronic colitis in TCRα−/− mice by i.p. injection of small amounts (10 μg/body) of saporin-conjugated anti-IL-7R mAb, once a week for 6 wk. Selective elimination of IL-7Rhigh LPLs by the administration of small amounts of
saporin-conjugated anti-IL-7R mAb completely ameliorated established colitis in TCRα−/− mice. Gross inspection of the colon in TCRα−/− mice revealed complete reduction of inflammatory activity after treatment with saporin-conjugated anti-IL-7R mAb, comparable with that in wild-type mice. In contrast, TCRα−/− mice treated with a mixture of free anti-IL-7R mAb and saporin (not conjugated) using the same protocol developed severe colitis, comparable with that in untreated TCRα−/− mice (Fig. 5A). Histological analysis of saporin-conjugated anti-IL-7R mAb-treated mice showed the dramatic decrease in colonic inflammation, comparable with the histology of the colonic mucosa in wild-type mice. In contrast, TCRα−/− mice treated with a mixture of free anti-IL-7R mAb and saporin developed severe colitis (Fig. 5B). The histological score assessing the severity of inflammation was significantly (p < 0.01) decreased after saporin-conjugated anti-IL-7R mAb treatment compared with that after treatment with a mixture of free anti-IL-7R mAb and saporin (Fig. 5C). Colonic wet weight and isolated total cell number of colonic LPLs were significantly (p < 0.001) decreased in TCRα−/− mice after saporin-conjugated anti-IL-7R mAb treatment compared with those after treatment with a mixture of free anti-IL-7R mAb and saporin (Fig. 5D). The decrease in colonic weight and total LPL number reached the level in wild-type mice. Flow cytometric analysis of isolated LPLs revealed that the degree of IL-7R expression on CD4+ LPLs from the colonic mucosa of TCRα−/− mice with chronic colitis was gradually and significantly (p < 0.01) decreased after saporin-conjugated anti-IL-7R mAb treatment (Fig. 5E). The decrease in IL-7R mAb, once a week for 6 wk. A. Gross inspection of the colon in TCRα−/− mice revealed a complete reduction in the inflammatory activity after treatment with saporin-conjugated anti-IL-7R mAb (n = 16), comparable to the colitis observed in wild-type mice (n = 20). In contrast, TCRα−/− mice treated with a mixture of free anti-IL-7R mAb and saporin (not conjugated) using the same protocol (n = 14) developed severe colitis, comparable to that in untreated TCRα−/− mice. B. Histological analysis of saporin-conjugated anti-IL-7R mAb-treated mice showed the dramatic decrease in colonic inflammation, comparable to the histology of the colonic mucosa in wild-type mice. In contrast, TCRα−/− mice treated with a mixture of free anti-IL-7R mAb and saporin developed severe colitis. C. The histological score was significantly (∗, p < 0.01) decreased after saporin-conjugated anti-IL-7R mAb treatment (n = 10) compared with that after treatment with a mixture of free anti-IL-7R mAb and saporin (n = 10). D. The colonic wet weight and isolated cell number of colonic LPLs were significantly (∗, p < 0.001) decreased in TCRα−/− mice after saporin-conjugated anti-IL-7R mAb treatment (n = 16) compared with those after treatment with a mixture of free anti-IL-7R mAb and saporin (n = 14). The decrease reached the level in wild-type mice. E. Flow cytometric analysis of isolated LPLs revealed that the degree of IL-7R expression on CD4+ LPLs from the colonic mucosa of TCRα−/− mice with chronic colitis was gradually and significantly (∗, p < 0.01; ∗∗, p < 0.001) decreased after saporin-conjugated anti-IL-7R mAb treatment. The decrease in IL-7R expression was more prominent after six treatments (6X; n = 16) than that after three treatments (3X; n = 5). F. Saporin-conjugated anti-IL-7R mAb treatment induced a significant (∗, p < 0.001) decrease in IL-7R expression on CD4+ LPLs in the colonic mucosa of TCRα−/− mice with chronic colitis (n = 16) compared with that after treatment with a mixture of free anti-IL-7R mAb and saporin (n = 14). The degree of IL-7R expression in CD4+ LPLs after treatment with a mixture of free anti-IL-7R mAb and saporin was comparable to that in untreated TCRα−/− mice (n = 20). G. Saporin-conjugated anti-IL-7R mAb treatment induced a significant (∗, p < 0.001) reduction in IL-2 production by CD4+ mucosal T cells after stimulation with anti-CD3 and anti-CD28 mAbs. IL-4 production increased in CD4+ LPLs from untreated TCRα−/− mice after the same stimulation. This increase was significantly (∗, p < 0.001) reduced in CD4+ LPLs from saporin-conjugated anti-IL-7R mAb-treated TCRα−/− mice, and production was below the level in wild-type mice. These data are representative of five separate series of experiments.
IL-7R expression was more prominent after six treatments than after three treatments. Subsequently, saporin-conjugated anti-IL-7R mAb treatment induced a significant \((p < 0.001)\) decrease in IL-7R expression on CD4\(^+\) LPLs in the colonic mucosa of TCR\(\alpha^-/^-\) mice with chronic colitis compared with that after treatment with a mixture of free anti-IL-7R mAb and saporin (Fig. 5F). The degree of IL-7R expression in CD4\(^+\) LPLs after treatment with a mixture of free anti-IL-7R mAb and saporin was comparable to that in untreated TCR\(\alpha^-/^-\) mice. Saporin-conjugated anti-IL-7R mAb treatment induced a significant \((p < 0.001)\) reduction in IL-2 production by CD4\(^+\) LPLs after stimulation with anti-CD3 and anti-CD28 mAbs (Fig. 5G). IL-4 production was increased in CD4\(^+\) LPLs from untreated TCR\(\alpha^-/^-\) mice after stimulation, and this increase was significantly \((p < 0.001)\) reduced to the level in wild-type mice in saporin-conjugated anti-IL-7R mAb-treated TCR\(\alpha^-/^-\) mice. These results indicate that successful treatment of established, ongoing chronic colitis was achieved by the selective elimination of LPLs expressing IL-7R at a high level without deletion of cells expressing with low or intermediate levels of IL-7R.

**Discussion**

A potential role for IL-7/IL-7R-mediated immune responses in the intestinal inflammation was unclear. We have demonstrated that IL-7 Tg mice developed chronic colitis that mimicked histopathological characteristics of human ulcerative colitis. In the colonic mucosa of IL-7 Tg mice with chronic colitis, a decrease in IL-7 protein accumulation in the epithelial cells and marked infiltration of IL-7R\(^{+}\) T cells in the lamina propria were demonstrable (10, 11). We also showed the decrease in IL-7 protein accumulation in the epithelial cells and infiltration of IL-7R\(^{+}\) T cells in the lamina propria at the chronic inflammation sites of patients with ulcerative colitis (our unpublished observations). These findings suggest that dysregulation of the mucosal IL-7/IL-7R system is a common phenomenon in chronic inflammation sites of the colonic mucosa. In the present study we confirmed this concept in various chronic colitis models. Interestingly, dysregulation of the mucosal IL-7/IL-7R system is not apparent in the acute colitis mouse model. This was consistent with our previous findings. In fact, IL-7 Tg mice developed acute colitis with infiltrating neutrophils and T cells at 1–3 wk of age. In the chronic colitis stage, IL-7 protein expression was significantly increased in the inflamed colonic mucosa. This contrasted with the decreased IL-7 expression in the chronic colitis stage, but was consistent with the findings that IL-7 expression was increased in colonic macrophages of patients with acute *Salmonella* enterocolitis and in severely inflamed mucosa in ulcerative colitis at acute exacerbation (our unpublished observations). The reason for substantial proliferation of mucosal IL-7R\(^{+}\) T cells in chronic colitis, although IL-7 expression in the epithelial cells is decreased, remains unclear. Recent reports indicated that the serum concentration of IL-7 is strongly related to CD4\(^+\) T cell lymphopenia, and IL-7 is produced by dendritic-like cells within peripheral lymphoid tissues in HIV disease (18). We are currently investigating the extraintestinal source of IL-7 in murine colitis models.

The most important finding of the present study was that attempts could be feasible in the treatment of chronic intestinal inflammation by the regulation of a mucosal IL-7R-dependent signaling pathway. Increasing evidence showed that chronic colitis in murine models has been successfully prevented by the administration of various mAbs or cytokines and by the establishment of double-knockout mice (19–21). However, few attempts resulted in adequate treatment of the established, ongoing colitis. We prevented chronic colitis in TCR\(\alpha^-/^-\) mice by establishment of TCR\(\alpha^-/^-\) \(\times\) IL-7R\(^{-}/^-\) double-knockout mice (our unpublished observation). Moreover, we successfully treated established, ongoing colitis in TCR\(\alpha^-/^-\) mice with Ab-based therapy targeting the IL-7R-dependent signaling pathway. We treated chronic colitis in TCR\(\alpha^-/^-\) mice by infusion of free and toxin-conjugated anti-IL-7R mAb. Blockade of the IL-7R-dependent signaling pathway by anti-IL-7R mAb partially abrogated established colitis (our unpublished observation). Importantly, selective elimination of IL-7R\(^{+}\) high T cells by the administration of small amounts of saporin-conjugated anti-IL-7R mAb completely ameliorated ongoing colitis in TCR\(\alpha^-/^-\) mice. This saporin-conjugated anti-IL-7R mAb did not inhibit the in vitro proliferation of CD4\(^+\) IL-7R\(^{+}\) spleen cells from normal mice, but did inhibit that of IL-7R\(^{+}\) high T cells from chronically inflamed mucosa of TCR\(\alpha^-/^-\) mice. This observation indicated that small amounts of saporin-conjugated anti-IL-7R mAb inhibited the proliferation or induced cell death of T cells expressing IL-7R at a high level that infiltrated in the chronic inflamed mucosa, but did not have an effect on cells expressing IL-7R at low or intermediate levels. This is explained by the fact that the amount of saporin binding to our anti-IL-7R mAb was extremely low. These results strongly confirmed that chronic inflammation in the colonic mucosa is mediated by the dysregulation of the mucosal IL-7/IL-7R signaling pathway. Treatment of wild-type mice with the same amount of saporin-conjugated anti-IL-7R mAb did not cause any change in the total cell number or a phenotypic change in spleen cells or LPLs. Deletion of IL-7R\(^{+}\) or CD4\(^+\) cells was not observed even after six treatments with 10 \(\mu\)g/body of saporin-conjugated anti-IL-7R mAb. Therefore, a therapy regulating LPLs expressing IL-7R at a high level is feasible in the treatment of chronic colitis without the deletion of cells expressing IL-7R at low or intermediate levels.

The mechanism by which the elimination of IL-7R\(^{+}\) high T cells leads to the amelioration of ongoing colitis should be defined. Our study showed that IL-7R\(^{+}\) high LPLs infiltrated in the lamina propria of colonic mucosa were activated and produced Th1- and Th2-type cytokines. Those activated IL-7R\(^{+}\) high mucosal T cells eventually produce inflammatory and proinflammatory cytokines that trigger a nonspecific inflammatory cascade. Therefore, it is not surprising that elimination of LPLs expressing IL-7R at a high level leads to the inhibition of ongoing colitis in chronic colitis mice.

Several clinical applications of IL-7 have been proposed, and many have been tested in mice (1, 22, 23). The major areas in which IL-7 appears to hold some clinical promise are antitumor activity, enhancement of lymphopoesis, promotion of stem cell engraftment, and enhanced antimicrobial activity. However, only a few clinical applications have been conducted targeting IL-7R-bearing cells. Only a single trial was proposed for the therapy for hematologic malignancies by toxin-based destruction of IL-7R-bearing cells. Sweeney et al. (24) have constructed a recombinant fusion protein, DAB389 IL-7, composed of the catalytic and transmembrane domains of diphtheria toxin, fused to IL-7. They demonstrated that DAB389 IL-7 has a selective cytotoxic effect only on cells bearing the IL-7R, and that entry into target cells was mediated through the receptor. These results indicated that DAB389 IL-7 may be a novel reagent that possesses potential as a therapeutic agent against IL-7R-bearing cell-mediated disorders. They have also constructed an IL-2 version of the diphtheria toxin-based fusion toxin, DAB-IL-2, and applied this to the treatment of cutaneous T cell lymphoma (25). Preliminary studies using DAB-IL-2 for the treatment of severe rheumatoid arthritis and severe methotrexate-resistant psoriasis have also been reported (26, 27). Therefore, DAB389 IL-7 may be promising in the treatment of disorders other than hematological malignancies. All previous attempts were conducted to eliminate every IL-7R-bearing cell. The
present study was the first attempt to eliminate only T cells expressing IL-7R at a high level by toxin-based destruction of cells for the treatment of nonmalignant disorders, and we are currently investigating whether DAB389 IL-7 is effective in the treatment of chronic colitis.

This study provides a basis for practical application of therapy targeting T cells expressing IL-7R at a high level for the treatment of chronic intestinal inflammation in human inflammatory bowel disease. Human inflammatory bowel disease is thought to result from an inappropriate activation of the mucosal immune system driven by luminal flora (28). The activation of key immune cell populations is eventually accompanied by the production of a wide variety of nonspecific mediators of inflammation, including various other immunologic and proinflammatory cytokines, chemokines, and growth factors. We suggest that T cells expressing IL-7R at a high level are one such key immune cell population. Therefore, therapeutic approaches targeting mucosal T cells expressing IL-7R at a high level may be feasible for the therapy of human inflammatory bowel disease.

Acknowledgments
We express special thanks to Prof. Hiroshi Kiyono and Dr. Masanobu Watanabe for providing RAG-2 mice; Dr. Tetsuo Sudo for providing anti-IL-7R mAb; Drs. Yoshitaka Ueno, Yasushi Iwao, and Noriaki Watanabe for technical assistance; and Yuko Ito for manuscript preparation.

References
9. Nanno for helpful discussion; Dr. Tatsuji Nomura and Kenichi Tamaoki for providing RAG-2 mice; Dr. Tetsuo Sudo for providing anti-IL-7R mAb; Drs. Yoshitaka Ueno, Yasushi Iwao, and Noriaki Watanabe for technical assistance; and Yuko Ito for manuscript preparation.

Acknowledgments
We express special thanks to Prof. Hiroshi Kiyono and Dr. Masanobu Watanabe for providing RAG-2 mice; Dr. Tetsuo Sudo for providing anti-IL-7R mAb; Drs. Yoshitaka Ueno, Yasushi Iwao, and Noriaki Watanabe for technical assistance; and Yuko Ito for manuscript preparation.

The Journal of Immunology